Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.

Mesguich, Charles; Cazeau, Anne-Laure; Bouabdallah, Krimo; Hindié, Elif

Mesguich, Charles; Cazeau, Anne-Laure; Bouabdallah, Krimo; Hindié, Elif.

Afiliação

Mesguich C; Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.
Cazeau AL; Department of Nuclear Medicine, Institut Bergonié Cancer Centre, Bordeaux, France.
Bouabdallah K; Department of Hematological Oncology, Bordeaux University Hospital, Bordeaux, France.
Hindié E; Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.

Br J Haematol ; 181(1): 124-125, 2018 04.

Article em En | MEDLINE | ID: mdl-28106255

Assuntos

Fluordesoxiglucose F18; Doença de Hodgkin; Criança; Humanos; Tomografia por Emissão de Pósitrons; Compostos Radiofarmacêuticos

Palavras-chave

Hodgkin lymphoma; imaging; lymphomas; positron emission tomography; prognostic factors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Fluordesoxiglucose F18 Tipo de estudo: Prognostic_studies Limite: Child / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google